Rapid SNP scanning

Mass spectrometry and pooled DNA samples allow for rapid genotyping of SNPs.

By | January 15, 2001

Single nucleotide polymorphisms (SNPs) are pouring into public databases, but methods for analyzing large numbers of SNPs in population studies lag behind. In the January 16 Proceedings of the National Academy of Sciences, Buetow et al. report that mass spectrometry (MS) and pooling of DNA samples can be combined to yield a rapid SNP genotyping method (Proc Natl Acad Sci USA 2001, 98:581-584). Buetow et al. define candidate SNPs as those sequences that show variation in multiple sequencing runs performed at Washington University (St Louis). DNA from 94 individuals is pooled, and candidate variable regions PCR-amplified. Low nanoliter aliquots are then transferred onto individual 200 μm elements of a 96-element silicon chip. This is the substrate for matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) MS. Less than four weeks of work confirms the polymorphism of, and yields accurate allele frequencies for, 3,646 SNPs. This is not yet enough for genome-wide studies of linkage disequilibrium, but suggests that an affordable system for carrying out such studies is not far off.

Popular Now

  1. UC Berkeley Receives CRISPR Patent in Europe
    Daily News UC Berkeley Receives CRISPR Patent in Europe

    The European Patent Office will grant patent rights over the use of CRISPR in all cell types to a University of California team, contrasting with a recent decision in the U.S.

  2. DNA Replication Errors Contribute to Cancer Risk
  3. Should Healthy People Have Their Exomes Sequenced?
    Daily News Should Healthy People Have Their Exomes Sequenced?

    With its announced launch of a whole-exome sequencing service for apparently healthy individuals, Ambry Genetics is the latest company to enter this growing market. But whether these services are useful for most people remains up for debate.  

  4. Rethinking a Cancer Drug Target
    Daily News Rethinking a Cancer Drug Target

    The results of a CRISPR-Cas9 study suggest that MELK—a protein thought to play a critical role in cancer—is not necessary for cancer cell survival.

Business Birmingham